UA124609C2 - Індоли для застосування при інфекції, спричиненій вірусом грипу - Google Patents
Індоли для застосування при інфекції, спричиненій вірусом грипу Download PDFInfo
- Publication number
- UA124609C2 UA124609C2 UAA201702154A UAA201702154A UA124609C2 UA 124609 C2 UA124609 C2 UA 124609C2 UA A201702154 A UAA201702154 A UA A201702154A UA A201702154 A UAA201702154 A UA A201702154A UA 124609 C2 UA124609 C2 UA 124609C2
- Authority
- UA
- Ukraine
- Prior art keywords
- mmol
- compound
- mixture
- amino
- methyl
- Prior art date
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims description 15
- 208000015181 infectious disease Diseases 0.000 title description 6
- 150000002475 indoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 176
- 206010022000 influenza Diseases 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 9
- 239000003443 antiviral agent Substances 0.000 claims description 8
- 229960003971 influenza vaccine Drugs 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 2
- 238000011260 co-administration Methods 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims 2
- 101150065749 Churc1 gene Proteins 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 180
- 239000000243 solution Substances 0.000 description 128
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 128
- 239000011541 reaction mixture Substances 0.000 description 106
- 238000002360 preparation method Methods 0.000 description 102
- 238000000034 method Methods 0.000 description 92
- 239000002904 solvent Substances 0.000 description 89
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 88
- 239000012044 organic layer Substances 0.000 description 88
- 239000007787 solid Substances 0.000 description 88
- 230000002829 reductive effect Effects 0.000 description 85
- 239000012071 phase Substances 0.000 description 84
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 68
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 67
- 239000000741 silica gel Substances 0.000 description 65
- 229910002027 silica gel Inorganic materials 0.000 description 65
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 62
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 61
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 59
- 230000015572 biosynthetic process Effects 0.000 description 56
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 48
- 239000012043 crude product Substances 0.000 description 48
- 238000003786 synthesis reaction Methods 0.000 description 46
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- 230000014759 maintenance of location Effects 0.000 description 35
- 238000000746 purification Methods 0.000 description 34
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- 238000001914 filtration Methods 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
- 235000019439 ethyl acetate Nutrition 0.000 description 32
- 239000000706 filtrate Substances 0.000 description 31
- 240000004270 Colocasia esculenta var. antiquorum Species 0.000 description 28
- -1 substituted Chemical class 0.000 description 27
- 239000010410 layer Substances 0.000 description 26
- 230000005526 G1 to G0 transition Effects 0.000 description 25
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 23
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 21
- 238000003818 flash chromatography Methods 0.000 description 19
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 19
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 18
- 239000012230 colorless oil Substances 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 18
- NKBWMBRPILTCRD-UHFFFAOYSA-N 2-Methylheptanoic acid Chemical compound CCCCCC(C)C(O)=O NKBWMBRPILTCRD-UHFFFAOYSA-N 0.000 description 17
- 239000012298 atmosphere Substances 0.000 description 17
- 239000012267 brine Substances 0.000 description 17
- LCDCPQHFCOBUEF-UHFFFAOYSA-N pyrrolidine-1-carboxamide Chemical compound NC(=O)N1CCCC1 LCDCPQHFCOBUEF-UHFFFAOYSA-N 0.000 description 17
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 229910052740 iodine Inorganic materials 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 15
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 150000004702 methyl esters Chemical class 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 241000282326 Felis catus Species 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 10
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 10
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 235000010469 Glycine max Nutrition 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 8
- DEDKKOOGYIMMBC-UHFFFAOYSA-N 2,6-dichloro-5-fluoropyridine-3-carbonitrile Chemical compound FC1=CC(C#N)=C(Cl)N=C1Cl DEDKKOOGYIMMBC-UHFFFAOYSA-N 0.000 description 7
- MCNQUWLLXZZZAC-UHFFFAOYSA-N 4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-n-piperidin-1-ylpyrazole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=C(C#N)C(C(=O)NN2CCCCC2)=NN1C1=CC=C(Cl)C=C1Cl MCNQUWLLXZZZAC-UHFFFAOYSA-N 0.000 description 7
- 206010002091 Anaesthesia Diseases 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 7
- 230000037005 anaesthesia Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- WHPFEQUEHBULBW-UHFFFAOYSA-N 2,4-dichloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1Cl WHPFEQUEHBULBW-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000005711 Benzoic acid Substances 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- ZCNXOOXHCDKUNZ-UHFFFAOYSA-N COC(C)(C)C(CC(O)=O)NC1=NC(C2=CNC3=C(F)C=C(F)C=C23)=C(C=C1F)C#N Chemical compound COC(C)(C)C(CC(O)=O)NC1=NC(C2=CNC3=C(F)C=C(F)C=C23)=C(C=C1F)C#N ZCNXOOXHCDKUNZ-UHFFFAOYSA-N 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- 235000010233 benzoic acid Nutrition 0.000 description 6
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 241000712431 Influenza A virus Species 0.000 description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000013504 emergency use authorization Methods 0.000 description 5
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000012047 saturated solution Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 5
- 235000019798 tripotassium phosphate Nutrition 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- NVOSZQUXIBXEAH-UHFFFAOYSA-N FC=1C=C(C=C2C(=CN(C=12)S(=O)(=O)C1=CC=C(C)C=C1)B1OC(C(O1)(C)C)(C)C)C Chemical compound FC=1C=C(C=C2C(=CN(C=12)S(=O)(=O)C1=CC=C(C)C=C1)B1OC(C(O1)(C)C)(C)C)C NVOSZQUXIBXEAH-UHFFFAOYSA-N 0.000 description 4
- 241000680386 Meonis Species 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 4
- 230000005587 bubbling Effects 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 208000037797 influenza A Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000001932 seasonal effect Effects 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WAGLGQXOHWSQOD-UHFFFAOYSA-N 2-fluoro-6-iodo-4-methylaniline Chemical compound CC1=CC(F)=C(N)C(I)=C1 WAGLGQXOHWSQOD-UHFFFAOYSA-N 0.000 description 3
- YQCCWZORPTUYNQ-UHFFFAOYSA-N 3-bromo-7-fluoro-5-methyl-1-(4-methylphenyl)sulfonylindole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=C(F)C=C(C)C=C2C(Br)=C1 YQCCWZORPTUYNQ-UHFFFAOYSA-N 0.000 description 3
- AORDVAXRGDICNT-UHFFFAOYSA-N 7-fluoro-5-methyl-1h-indole Chemical compound CC1=CC(F)=C2NC=CC2=C1 AORDVAXRGDICNT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- NTGOMARXAQOTQY-UHFFFAOYSA-N BrC1=CN(C2=C(C=C(C=C12)C#N)F)S(=O)(=O)C1=CC=C(C)C=C1 Chemical compound BrC1=CN(C2=C(C=C(C=C12)C#N)F)S(=O)(=O)C1=CC=C(C)C=C1 NTGOMARXAQOTQY-UHFFFAOYSA-N 0.000 description 3
- FNIMHVTVWZMNCU-RJUBDTSPSA-N Cl.N[C@H]1C[C@H](CCC1)NC1=NC(=C(C#N)C=C1F)Cl Chemical compound Cl.N[C@H]1C[C@H](CCC1)NC1=NC(=C(C#N)C=C1F)Cl FNIMHVTVWZMNCU-RJUBDTSPSA-N 0.000 description 3
- CCMVNXYIWFELQB-UHFFFAOYSA-N ClC1=CC(F)=C2NC=C(C2=C1)I Chemical compound ClC1=CC(F)=C2NC=C(C2=C1)I CCMVNXYIWFELQB-UHFFFAOYSA-N 0.000 description 3
- KCXHZFYNZSHRFB-UHFFFAOYSA-N ClC=1C=C2C(=CN(C2=C(C=1)F)C(=O)OC(C)(C)C)B1OC(C(O1)(C)C)(C)C Chemical compound ClC=1C=C2C(=CN(C2=C(C=1)F)C(=O)OC(C)(C)C)B1OC(C(O1)(C)C)(C)C KCXHZFYNZSHRFB-UHFFFAOYSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- UMXMCLFPJZLIJJ-UHFFFAOYSA-N FC=1C=C(C=C2C(=CN(C=12)S(=O)(=O)C1=CC=C(C)C=C1)B1OC(C(O1)(C)C)(C)C)C#N Chemical compound FC=1C=C(C=C2C(=CN(C=12)S(=O)(=O)C1=CC=C(C)C=C1)B1OC(C(O1)(C)C)(C)C)C#N UMXMCLFPJZLIJJ-UHFFFAOYSA-N 0.000 description 3
- CMZIOEHDNBEXBD-UHFFFAOYSA-N FC=1C=C(C=C2C=CN(C=12)S(=O)(=O)C1=CC=C(C)C=C1)C Chemical compound FC=1C=C(C=C2C=CN(C=12)S(=O)(=O)C1=CC=C(C)C=C1)C CMZIOEHDNBEXBD-UHFFFAOYSA-N 0.000 description 3
- OKMLXDNGIIPDQH-UHFFFAOYSA-N FC=1C=C(C=C2C=CN(C=12)S(=O)(=O)C1=CC=C(C)C=C1)C#N Chemical compound FC=1C=C(C=C2C=CN(C=12)S(=O)(=O)C1=CC=C(C)C=C1)C#N OKMLXDNGIIPDQH-UHFFFAOYSA-N 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 101710154606 Hemagglutinin Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 102000005348 Neuraminidase Human genes 0.000 description 3
- 108010006232 Neuraminidase Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 3
- 101710176177 Protein A56 Proteins 0.000 description 3
- 229910020163 SiOCl Inorganic materials 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 208000037798 influenza B Diseases 0.000 description 3
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 3
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 229910052720 vanadium Inorganic materials 0.000 description 3
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 2
- WZTRQGJMMHMFGH-UHFFFAOYSA-N 1-methyl-imidazole-4-carboxylic acid Chemical compound CN1C=NC(C(O)=O)=C1 WZTRQGJMMHMFGH-UHFFFAOYSA-N 0.000 description 2
- ZUGYJALETFVYJV-UHFFFAOYSA-N 1-methylcyclopentane-1-carbaldehyde Chemical compound O=CC1(C)CCCC1 ZUGYJALETFVYJV-UHFFFAOYSA-N 0.000 description 2
- OZYDARRKCCHJOL-UHFFFAOYSA-N 1-methylcyclopentane-1-carbonitrile Chemical compound N#CC1(C)CCCC1 OZYDARRKCCHJOL-UHFFFAOYSA-N 0.000 description 2
- VVXQCTFINCODIF-UHFFFAOYSA-N 2,6-dichloro-3-fluoro-5-(trifluoromethyl)pyridine Chemical compound FC1=CC(C(F)(F)F)=C(Cl)N=C1Cl VVXQCTFINCODIF-UHFFFAOYSA-N 0.000 description 2
- SFFSGPCYJCMDJM-UHFFFAOYSA-N 2-[2-(3-oxo-1,2-benzoselenazol-2-yl)ethyl]-1,2-benzoselenazol-3-one Chemical compound [se]1C2=CC=CC=C2C(=O)N1CCN1C(=O)C(C=CC=C2)=C2[se]1 SFFSGPCYJCMDJM-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- WZPOGQRJXZGSMH-UHFFFAOYSA-N 5,7-difluoro-1h-indole Chemical compound FC1=CC(F)=C2NC=CC2=C1 WZPOGQRJXZGSMH-UHFFFAOYSA-N 0.000 description 2
- QIACATCUODRSLS-UHFFFAOYSA-N 5-methyl-1,3-oxazole-4-carboxylic acid Chemical compound CC=1OC=NC=1C(O)=O QIACATCUODRSLS-UHFFFAOYSA-N 0.000 description 2
- 241000283725 Bos Species 0.000 description 2
- UVWAQDSXPNIJKF-UHFFFAOYSA-N BrC1=CN(C2=C(C=C(C=C12)F)F)S(=O)(=O)C1=CC=C(C)C=C1 Chemical compound BrC1=CN(C2=C(C=C(C=C12)F)F)S(=O)(=O)C1=CC=C(C)C=C1 UVWAQDSXPNIJKF-UHFFFAOYSA-N 0.000 description 2
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- QWSRWKWHNGDZEH-ZJUUUORDSA-N ClC1=NC=C(C(=N1)N[C@H]1C[C@H](CCC1)NC(OC(C)(C)C)=O)F Chemical compound ClC1=NC=C(C(=N1)N[C@H]1C[C@H](CCC1)NC(OC(C)(C)C)=O)F QWSRWKWHNGDZEH-ZJUUUORDSA-N 0.000 description 2
- VNBYLAQTENYYTJ-UHFFFAOYSA-N ClC=1C=C2C(=CN(C2=C(C=1)F)C(=O)OC(C)(C)C)I Chemical compound ClC=1C=C2C(=CN(C2=C(C=1)F)C(=O)OC(C)(C)C)I VNBYLAQTENYYTJ-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- FQQFREGJTCXKLR-UHFFFAOYSA-N FC=1C=C2C(=CN(C2=C(C=1)F)S(=O)(=O)C1=CC=C(C)C=C1)B1OC(C(O1)(C)C)(C)C Chemical compound FC=1C=C2C(=CN(C2=C(C=1)F)S(=O)(=O)C1=CC=C(C)C=C1)B1OC(C(O1)(C)C)(C)C FQQFREGJTCXKLR-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 101100006982 Mus musculus Ppcdc gene Proteins 0.000 description 2
- 241000549435 Pria Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241001178076 Zaga Species 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 238000010533 azeotropic distillation Methods 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000003963 dichloro group Chemical group Cl* 0.000 description 2
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Substances CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- RPZHFKHTXCZXQV-UHFFFAOYSA-N mercury(I) oxide Inorganic materials O1[Hg][Hg]1 RPZHFKHTXCZXQV-UHFFFAOYSA-N 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- KNXJJBFMNGIONQ-UHFFFAOYSA-N n,n-diethyl-2-(5-methylpyridazino[3,4-b][1,4]benzoxazin-3-yl)oxyethanamine;dihydrochloride Chemical compound Cl.Cl.CN1C2=CC=CC=C2OC2=C1C=C(OCCN(CC)CC)N=N2 KNXJJBFMNGIONQ-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- AELQFRLRNCJZQE-UHFFFAOYSA-N octyl-di(propan-2-yl)silane Chemical compound CCCCCCCC[SiH](C(C)C)C(C)C AELQFRLRNCJZQE-UHFFFAOYSA-N 0.000 description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 2
- 229960003752 oseltamivir Drugs 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000004237 preparative chromatography Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229960000888 rimantadine Drugs 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000002911 sialidase inhibitor Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
- JNOGVQJEBGEKMG-UHFFFAOYSA-N (1-methoxy-2-methylprop-1-enoxy)-trimethylsilane Chemical compound COC(=C(C)C)O[Si](C)(C)C JNOGVQJEBGEKMG-UHFFFAOYSA-N 0.000 description 1
- JSGHMGKJNZTKGF-DTWKUNHWSA-N (1s,3r)-3-[(2-methylpropan-2-yl)oxycarbonylamino]cyclohexane-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCC[C@H](C(O)=O)C1 JSGHMGKJNZTKGF-DTWKUNHWSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- HJVCHYDYCYBBQX-HLTLHRPFSA-N (2s,3s,4e,6e,8s,9s)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid Chemical compound OC(=O)[C@@H](C)[C@@H](N)/C=C/C(/C)=C/[C@H](C)[C@@H](OC)CC1=CC=CC=C1 HJVCHYDYCYBBQX-HLTLHRPFSA-N 0.000 description 1
- KKVNENSFUWDQCF-BWHNGHDOSA-N (8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol;(6s,8r,9s,10r,13s,14s,17s)-17-hydroxy-6,10,13-trimethyl-17-prop-1-ynyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1([C@@H](C)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C#CC)(O)[C@@]2(C)CC1 KKVNENSFUWDQCF-BWHNGHDOSA-N 0.000 description 1
- PPKPKFIWDXDAGC-IHWYPQMZSA-N (z)-1,2-dichloroprop-1-ene Chemical compound C\C(Cl)=C\Cl PPKPKFIWDXDAGC-IHWYPQMZSA-N 0.000 description 1
- YZVFSQQHQPPKNX-UHFFFAOYSA-N 1,3-thiazole-5-carboxylic acid Chemical compound OC(=O)C1=CN=CS1 YZVFSQQHQPPKNX-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- QUYJEYSRBCLJIZ-UHFFFAOYSA-N 1-methylpyrazole-3-carbaldehyde Chemical compound CN1C=CC(C=O)=N1 QUYJEYSRBCLJIZ-UHFFFAOYSA-N 0.000 description 1
- ZEBFPAXSQXIPNF-UHFFFAOYSA-N 2,5-dimethylpyrrolidine Chemical compound CC1CCC(C)N1 ZEBFPAXSQXIPNF-UHFFFAOYSA-N 0.000 description 1
- QLBGFCHJCWNVIN-UHFFFAOYSA-N 2-(1,3-thiazol-2-yl)acetonitrile Chemical compound N#CCC1=NC=CS1 QLBGFCHJCWNVIN-UHFFFAOYSA-N 0.000 description 1
- ZQEXBVHABAJPHJ-UHFFFAOYSA-N 2-fluoro-4-methylaniline Chemical compound CC1=CC=C(N)C(F)=C1 ZQEXBVHABAJPHJ-UHFFFAOYSA-N 0.000 description 1
- QCXCIYPOMMIBHO-UHFFFAOYSA-N 2-methyl-1,3-thiazole-5-carboxylic acid Chemical compound CC1=NC=C(C(O)=O)S1 QCXCIYPOMMIBHO-UHFFFAOYSA-N 0.000 description 1
- ZJHBNGNAZSITGO-UHFFFAOYSA-N 2-methyl-2-(1,3-thiazol-2-yl)propanenitrile Chemical compound N#CC(C)(C)C1=NC=CS1 ZJHBNGNAZSITGO-UHFFFAOYSA-N 0.000 description 1
- FUTYAVSMXILTHT-UHFFFAOYSA-N 2-methyl-2-(1-methylpyrazol-3-yl)propanenitrile Chemical compound CN1C=CC(C(C)(C)C#N)=N1 FUTYAVSMXILTHT-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- GRNHLFULJDXJKR-UHFFFAOYSA-N 3-(2-sulfanylethyl)-1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)N(CCS)C(=O)NC2=C1 GRNHLFULJDXJKR-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- MIMSUZKTGRXZNZ-UHFFFAOYSA-N 3-azaniumyl-4,4-dimethylpentanoate Chemical compound CC(C)(C)C(N)CC(O)=O MIMSUZKTGRXZNZ-UHFFFAOYSA-N 0.000 description 1
- RJXSLLLKTBOEEA-UHFFFAOYSA-N 3-isocyanatooxolane Chemical compound O=C=NC1CCOC1 RJXSLLLKTBOEEA-UHFFFAOYSA-N 0.000 description 1
- PBEDVTDUVXFSMW-UHFFFAOYSA-N 3-methylimidazole-4-carboxylic acid Chemical compound CN1C=NC=C1C(O)=O PBEDVTDUVXFSMW-UHFFFAOYSA-N 0.000 description 1
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 description 1
- UCFSYHMCKWNKAH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 1
- AZASWMGVGQEVCS-UHFFFAOYSA-N 4,4-dimethylpentan-2-one Chemical compound CC(=O)CC(C)(C)C AZASWMGVGQEVCS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- YTMYUWVMZMIXFO-UHFFFAOYSA-N 5,5-dimethylcyclohexane-1,3-diamine Chemical compound CC1(C)CC(N)CC(N)C1 YTMYUWVMZMIXFO-UHFFFAOYSA-N 0.000 description 1
- ALVWLRRLYMWPAJ-UHFFFAOYSA-N 5-chloro-7-fluoro-1h-indole Chemical compound FC1=CC(Cl)=CC2=C1NC=C2 ALVWLRRLYMWPAJ-UHFFFAOYSA-N 0.000 description 1
- OIWNDJQQIMISPC-UHFFFAOYSA-N 5-methyl-1,3-thiazole-4-carboxylic acid Chemical compound CC=1SC=NC=1C(O)=O OIWNDJQQIMISPC-UHFFFAOYSA-N 0.000 description 1
- RBYJWCRKFLGNDB-UHFFFAOYSA-N 5-methylpyrazine-2-carboxylic acid Chemical compound CC1=CN=C(C(O)=O)C=N1 RBYJWCRKFLGNDB-UHFFFAOYSA-N 0.000 description 1
- XPJWXNPTGJIGIL-UHFFFAOYSA-N 7-fluoro-1h-indole-5-carbonitrile Chemical compound FC1=CC(C#N)=CC2=C1NC=C2 XPJWXNPTGJIGIL-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 241000258740 Abia Species 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 102100040439 Adenylate kinase 4, mitochondrial Human genes 0.000 description 1
- 108050004095 Adenylate kinase 4, mitochondrial Proteins 0.000 description 1
- 244000005894 Albizia lebbeck Species 0.000 description 1
- 241000144080 Alestes Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 101000995861 Arabidopsis thaliana Regulatory protein NPR1 Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000238017 Astacoidea Species 0.000 description 1
- 240000005220 Bischofia javanica Species 0.000 description 1
- 235000010893 Bischofia javanica Nutrition 0.000 description 1
- XYGKGASSKJWLTN-UHFFFAOYSA-N CCCCCCC.CCCCCCC Chemical compound CCCCCCC.CCCCCCC XYGKGASSKJWLTN-UHFFFAOYSA-N 0.000 description 1
- 101100392078 Caenorhabditis elegans cat-4 gene Proteins 0.000 description 1
- 101100098216 Caenorhabditis elegans rars-1 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 240000008365 Celosia argentea Species 0.000 description 1
- 235000000722 Celosia argentea Nutrition 0.000 description 1
- 241000700112 Chinchilla Species 0.000 description 1
- 241001342895 Chorus Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- DQSBHRFBJFQRFN-UHFFFAOYSA-N ClC1=NC=C(C(=N1)NC(CC(=O)OCC)C(C)(C)C)F Chemical compound ClC1=NC=C(C(=N1)NC(CC(=O)OCC)C(C)(C)C)F DQSBHRFBJFQRFN-UHFFFAOYSA-N 0.000 description 1
- 241000543381 Cliftonia monophylla Species 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
- 101100275990 Drosophila melanogaster Naus gene Proteins 0.000 description 1
- 101100301524 Drosophila melanogaster Reg-5 gene Proteins 0.000 description 1
- 241000826056 Elioraea Species 0.000 description 1
- 240000008187 Erythrina edulis Species 0.000 description 1
- 235000002757 Erythrina edulis Nutrition 0.000 description 1
- OGSBHFKFSCGLRT-UHFFFAOYSA-N FC1=C(N)C(=CC(=C1)C)C#C[Si](C)(C)C Chemical compound FC1=C(N)C(=CC(=C1)C)C#C[Si](C)(C)C OGSBHFKFSCGLRT-UHFFFAOYSA-N 0.000 description 1
- APWDCRZUIYPXHZ-UHFFFAOYSA-N FC=1C(=NC(=NC=1)C1=CN(C2=C(C=C(C=C12)C)F)S(=O)(=O)C1=CC=C(C)C=C1)NC(CC(=O)OCC)C(C)(C)C Chemical compound FC=1C(=NC(=NC=1)C1=CN(C2=C(C=C(C=C12)C)F)S(=O)(=O)C1=CC=C(C)C=C1)NC(CC(=O)OCC)C(C)(C)C APWDCRZUIYPXHZ-UHFFFAOYSA-N 0.000 description 1
- DTSMIBOTXQWSMF-RPWUZVMVSA-N FC=1C=C2C(=CN(C2=C(C=1)F)S(=O)(=O)C1=CC=C(C)C=C1)C1=C(C=C(C(=N1)N[C@H]1C[C@H](CCC1)NC(OCC1=CC=CC=C1)=O)F)C(F)(F)F Chemical compound FC=1C=C2C(=CN(C2=C(C=1)F)S(=O)(=O)C1=CC=C(C)C=C1)C1=C(C=C(C(=N1)N[C@H]1C[C@H](CCC1)NC(OCC1=CC=CC=C1)=O)F)C(F)(F)F DTSMIBOTXQWSMF-RPWUZVMVSA-N 0.000 description 1
- ISCGMQGSKVGLGG-UHFFFAOYSA-N FC=1C=C2C(=CNC2=C(C=1)F)C1=C(C=C(C(=N1)NC(CC(=O)O)C(C)(C)C)F)C(F)(F)F Chemical compound FC=1C=C2C(=CNC2=C(C=1)F)C1=C(C=C(C(=N1)NC(CC(=O)O)C(C)(C)C)F)C(F)(F)F ISCGMQGSKVGLGG-UHFFFAOYSA-N 0.000 description 1
- BXFWPKAXYBXUDG-UHFFFAOYSA-N FC=1C=C2C=CN(C2=C(C=1)F)S(=O)(=O)C1=CC=C(C)C=C1 Chemical compound FC=1C=C2C=CN(C2=C(C=1)F)S(=O)(=O)C1=CC=C(C)C=C1 BXFWPKAXYBXUDG-UHFFFAOYSA-N 0.000 description 1
- 241000755093 Gaidropsarus vulgaris Species 0.000 description 1
- 241000828585 Gari Species 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 101000600885 Homo sapiens Serine/threonine-protein kinase NIM1 Proteins 0.000 description 1
- 241000692870 Inachis io Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 241000713297 Influenza C virus Species 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 1
- 241001547328 Kerya Species 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000408529 Libra Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000343235 Maso Species 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 241001214257 Mene Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 206010027627 Miliaria Diseases 0.000 description 1
- 101100237844 Mus musculus Mmp19 gene Proteins 0.000 description 1
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 1
- 241000761518 Myro Species 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- WMNOLOMGSDHERX-UHFFFAOYSA-N NC(=CC(=O)OCC)C(C)(C1=NN(C=C1)C)C Chemical compound NC(=CC(=O)OCC)C(C)(C1=NN(C=C1)C)C WMNOLOMGSDHERX-UHFFFAOYSA-N 0.000 description 1
- UIOHCSYQLGZCRJ-UHFFFAOYSA-N NCC=1C=C(C(=NC=1C1=CNC2=C(C=C(C=C12)F)F)NC(CC(=O)OC)C(C)(C)C)F Chemical compound NCC=1C=C(C(=NC=1C1=CNC2=C(C=C(C=C12)F)F)NC(CC(=O)OC)C(C)(C)C)F UIOHCSYQLGZCRJ-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241001611408 Nebo Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100366988 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) stu-1 gene Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- UARFUTKKOUUNRU-UHFFFAOYSA-N OC(=O)n1cc(I)c2cc(Cl)cc(F)c12 Chemical compound OC(=O)n1cc(I)c2cc(Cl)cc(F)c12 UARFUTKKOUUNRU-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 1
- 101150024701 PPH3 gene Proteins 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000634212 Penia Species 0.000 description 1
- 240000002134 Pentadesma butyracea Species 0.000 description 1
- 235000000857 Pentadesma butyracea Nutrition 0.000 description 1
- 241001387976 Pera Species 0.000 description 1
- 241000269799 Perca fluviatilis Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 241001377010 Pila Species 0.000 description 1
- 240000005546 Piper methysticum Species 0.000 description 1
- 235000016787 Piper methysticum Nutrition 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000159610 Roya <green alga> Species 0.000 description 1
- 208000027066 STING-associated vasculopathy with onset in infancy Diseases 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 101100449817 Schizosaccharomyces pombe (strain 972 / ATCC 24843) gto2 gene Proteins 0.000 description 1
- 102100037345 Serine/threonine-protein kinase NIM1 Human genes 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 229910006898 SnSi Inorganic materials 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 241000718541 Tetragastris balsamifera Species 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 240000001085 Trapa natans Species 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 241000270506 Tupinambis Species 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 101100020289 Xenopus laevis koza gene Proteins 0.000 description 1
- GAZVSNAEUUUDEK-JDSLSITLSA-N [(1r,3r,4s)-4,7,7-trimethyl-3-bicyclo[2.2.1]heptanyl] 2-hydroxybenzoate Chemical compound O([C@H]1[C@@]2(C)CC[C@H](C1)C2(C)C)C(=O)C1=CC=CC=C1O GAZVSNAEUUUDEK-JDSLSITLSA-N 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- UELITFHSCLAHKR-UHFFFAOYSA-N acibenzolar-S-methyl Chemical compound CSC(=O)C1=CC=CC2=C1SN=N2 UELITFHSCLAHKR-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- NFWZARAFTINKJK-OLZOCXBDSA-N benzyl n-[(1s,3r)-3-aminocyclohexyl]carbamate Chemical compound C1[C@H](N)CCC[C@@H]1NC(=O)OCC1=CC=CC=C1 NFWZARAFTINKJK-OLZOCXBDSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- MNRNSFOFHFYHNP-UHFFFAOYSA-N cyclohexane-1,3-diamine Chemical compound NC1[CH]CCC(N)C1 MNRNSFOFHFYHNP-UHFFFAOYSA-N 0.000 description 1
- MVUYVVKSXCLYSP-UHFFFAOYSA-N cyclohexane-1,3-diamine;hydrochloride Chemical compound Cl.NC1CCCC(N)C1 MVUYVVKSXCLYSP-UHFFFAOYSA-N 0.000 description 1
- SVPZJHKVRMRREG-UHFFFAOYSA-N cyclopentanecarbonitrile Chemical compound N#CC1CCCC1 SVPZJHKVRMRREG-UHFFFAOYSA-N 0.000 description 1
- HAORKNGNJCEJBX-UHFFFAOYSA-N cyprodinil Chemical compound N=1C(C)=CC(C2CC2)=NC=1NC1=CC=CC=C1 HAORKNGNJCEJBX-UHFFFAOYSA-N 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- IIJREXIVDSIOFR-UHFFFAOYSA-N dichloromethane;heptane Chemical compound ClCCl.CCCCCCC IIJREXIVDSIOFR-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- OLGIDLDDXHSYFE-UHFFFAOYSA-N dihydridotin Chemical compound [SnH2] OLGIDLDDXHSYFE-UHFFFAOYSA-N 0.000 description 1
- OBDWNWOYULJOBW-UHFFFAOYSA-N dimethylphosphinite dimethylphosphinous acid platinum(2+) Chemical compound [Pt++].CP(C)O.CP(C)[O-].CP(C)[O-] OBDWNWOYULJOBW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 229940125371 direct-acting antiviral drugs Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- XWRLQRLQUKZEEU-UHFFFAOYSA-N ethyl(hydroxy)silicon Chemical group CC[Si]O XWRLQRLQUKZEEU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000010438 granite Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 125000001145 hydrido group Chemical group *[H] 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- UKOFUFBBXOWCNO-UHFFFAOYSA-N methyl 3-amino-4,4-dimethylpentanoate Chemical compound COC(=O)CC(N)C(C)(C)C UKOFUFBBXOWCNO-UHFFFAOYSA-N 0.000 description 1
- 239000008833 migu Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000004651 near-field scanning optical microscopy Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- PBLZLIFKVPJDCO-UHFFFAOYSA-N omega-Aminododecanoic acid Natural products NCCCCCCCCCCCC(O)=O PBLZLIFKVPJDCO-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- XJEDAYAKFYAHIF-UHFFFAOYSA-N oxane-3,5-diamine Chemical compound NC1COCC(N)C1 XJEDAYAKFYAHIF-UHFFFAOYSA-N 0.000 description 1
- SMIQVIXGQSMHKF-UHFFFAOYSA-N oxane-3,5-dione Chemical compound O=C1COCC(=O)C1 SMIQVIXGQSMHKF-UHFFFAOYSA-N 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 235000011835 quiches Nutrition 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229910000679 solder Inorganic materials 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical compound NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940081330 tena Drugs 0.000 description 1
- CESUXLKAADQNTB-UHFFFAOYSA-N tert-butanesulfinamide Chemical compound CC(C)(C)S(N)=O CESUXLKAADQNTB-UHFFFAOYSA-N 0.000 description 1
- OBSACSBMTRJNPH-UHFFFAOYSA-N tert-butyl n-(3-aminocyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCCC(N)C1 OBSACSBMTRJNPH-UHFFFAOYSA-N 0.000 description 1
- OBSACSBMTRJNPH-BDAKNGLRSA-N tert-butyl n-[(1s,3r)-3-aminocyclohexyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CCC[C@@H](N)C1 OBSACSBMTRJNPH-BDAKNGLRSA-N 0.000 description 1
- XGTPDIIFEPTULX-UHFFFAOYSA-N tert-butyl prop-2-ynoate Chemical compound CC(C)(C)OC(=O)C#C XGTPDIIFEPTULX-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- GGNIKGLUPSHSBV-UHFFFAOYSA-N thiazole-5-carboxamide Chemical compound NC(=O)C1=CN=CS1 GGNIKGLUPSHSBV-UHFFFAOYSA-N 0.000 description 1
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 230000005924 vaccine-induced immune response Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000013522 vodka Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14180331 | 2014-08-08 | ||
| PCT/EP2015/068257 WO2016020526A1 (en) | 2014-08-08 | 2015-08-07 | Indoles for use in influenza virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA124609C2 true UA124609C2 (uk) | 2021-10-20 |
Family
ID=51298610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201702154A UA124609C2 (uk) | 2014-08-08 | 2015-08-07 | Індоли для застосування при інфекції, спричиненій вірусом грипу |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10597390B2 (https=) |
| EP (1) | EP3177609A1 (https=) |
| JP (1) | JP6577570B2 (https=) |
| KR (1) | KR102488479B1 (https=) |
| CN (1) | CN106573920B (https=) |
| AU (1) | AU2015298876B2 (https=) |
| BR (1) | BR112017002370B1 (https=) |
| CA (1) | CA2954751C (https=) |
| CL (1) | CL2017000309A1 (https=) |
| EA (1) | EA201790266A1 (https=) |
| IL (1) | IL250408B (https=) |
| MA (1) | MA40547A (https=) |
| MX (1) | MX381488B (https=) |
| PH (1) | PH12017500207A1 (https=) |
| SG (1) | SG11201700956VA (https=) |
| UA (1) | UA124609C2 (https=) |
| WO (1) | WO2016020526A1 (https=) |
| ZA (1) | ZA201700952B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3141252T (lt) | 2009-06-17 | 2018-11-12 | Vertex Pharmaceuticals Inc. | Gripo virusų replikacijos inhibitoriai |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| CN106573920B (zh) | 2014-08-08 | 2020-11-10 | 爱尔兰詹森科学公司 | 用于在流感病毒感染中使用的吲哚 |
| EP3294717B1 (en) | 2015-05-13 | 2020-07-29 | Vertex Pharmaceuticals Inc. | Methods of preparing inhibitors of influenza viruses replication |
| EP3294735B8 (en) | 2015-05-13 | 2022-01-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| SG11201804225PA (en) | 2015-12-09 | 2018-06-28 | Sunshine Lake Pharma Co Ltd | Inhibitors of influenza virus replication, application methods and uses thereof |
| DK3400225T3 (da) * | 2016-01-07 | 2022-01-03 | Janssen Sciences Ireland Unlimited Co | Pentansyrederivater substitueret med pyrrolo-[2,3-b]pyrimidinpyridiner til behandling af influenzavirusinfektioner |
| WO2017133670A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza |
| WO2018033082A1 (en) * | 2016-08-16 | 2018-02-22 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| WO2018041091A1 (en) * | 2016-08-30 | 2018-03-08 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| RU2727772C1 (ru) | 2016-09-05 | 2020-07-23 | Гуандун Рэйновент Байотек Ко., Лтд. | Производные пиримидина против вируса гриппа |
| JP7034162B2 (ja) | 2016-12-15 | 2022-03-11 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | インフルエンザウイルス複製の阻害剤及びその使用 |
| CA3047404A1 (en) * | 2016-12-23 | 2018-06-28 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use |
| CN108276401B (zh) | 2017-01-05 | 2020-12-22 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其用途 |
| WO2018157830A1 (en) | 2017-03-02 | 2018-09-07 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| CN108727369B (zh) * | 2017-04-25 | 2023-06-09 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其用途 |
| JP7031002B2 (ja) | 2018-03-05 | 2022-03-07 | 広東衆生睿創生物科技有限公司 | ピリジノイミダゾール系化合物の結晶型、塩型及びその製造方法 |
| WO2021012864A1 (zh) * | 2019-07-22 | 2021-01-28 | 广东众生睿创生物科技有限公司 | 嘧啶衍生物的优势盐型及其晶型 |
| CN113045475A (zh) * | 2019-12-27 | 2021-06-29 | 上海泓博智源医药股份有限公司 | 一种5-溴-7-甲基吲哚的制备方法 |
| AU2021313150A1 (en) * | 2020-07-20 | 2023-03-16 | Nido Biosciences, Inc. | Indole compounds as androgen receptor modulators |
| EP4214201A4 (en) * | 2020-09-18 | 2024-10-09 | Sunshine Lake Pharma Co., Ltd. | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIMIDINE PIPERAZINE COMPOUNDS |
| CR20250176A (es) * | 2022-10-12 | 2025-06-25 | Maze Therapeutics Inc | Inhibidores del miembro 19 de la familia de portadores de solutos 6a (slc6a19) y métodos de uso de los mismos |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2364340T3 (es) | 2004-03-30 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | Azaindoles útiles como inhibidores de jak y otras proteína quinasas. |
| UA95940C2 (uk) | 2006-01-17 | 2011-09-26 | Вертекс Фармасьютикалс Інкорпорейтед | Азаіндоли як інгібітори кіназ януса |
| LT3141252T (lt) * | 2009-06-17 | 2018-11-12 | Vertex Pharmaceuticals Inc. | Gripo virusų replikacijos inhibitoriai |
| US9326987B2 (en) * | 2010-09-08 | 2016-05-03 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
| RU2013132681A (ru) * | 2010-12-16 | 2015-01-27 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы репликации вирусов гриппа |
| CN103562205A (zh) * | 2010-12-16 | 2014-02-05 | 沃泰克斯药物股份有限公司 | 流感病毒复制的抑制剂 |
| UA118010C2 (uk) * | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| JP6096778B2 (ja) | 2011-09-01 | 2017-03-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ピロロピラジンキナーゼ阻害剤 |
| EP2858984A1 (en) | 2012-06-08 | 2015-04-15 | Vertex Pharmaceuticals Inc. | Inhibitors of influenza viruses replication |
| LT3068776T (lt) | 2013-11-13 | 2019-08-12 | Vertex Pharmaceuticals Incorporated | Gripo virusų replikacijos inhibitoriai |
| AR101448A1 (es) | 2014-08-08 | 2016-12-21 | Bayer Cropscience Ag | Compuestos sustituidos por halógeno |
| CN106573920B (zh) | 2014-08-08 | 2020-11-10 | 爱尔兰詹森科学公司 | 用于在流感病毒感染中使用的吲哚 |
| AR101401A1 (es) | 2014-08-08 | 2016-12-14 | Bayer Cropscience Ag | Derivados de bipirazol, sustituidos con halógeno |
| CN104592038A (zh) | 2015-01-12 | 2015-05-06 | 烟台万润精细化工股份有限公司 | 一种5,5-二甲基-1,3-环己二胺的制备方法 |
-
2015
- 2015-08-07 CN CN201580042406.9A patent/CN106573920B/zh not_active Expired - Fee Related
- 2015-08-07 WO PCT/EP2015/068257 patent/WO2016020526A1/en not_active Ceased
- 2015-08-07 EA EA201790266A patent/EA201790266A1/ru unknown
- 2015-08-07 MX MX2017001752A patent/MX381488B/es unknown
- 2015-08-07 CA CA2954751A patent/CA2954751C/en active Active
- 2015-08-07 AU AU2015298876A patent/AU2015298876B2/en not_active Ceased
- 2015-08-07 SG SG11201700956VA patent/SG11201700956VA/en unknown
- 2015-08-07 EP EP15750365.7A patent/EP3177609A1/en not_active Withdrawn
- 2015-08-07 BR BR112017002370-9A patent/BR112017002370B1/pt not_active IP Right Cessation
- 2015-08-07 MA MA040547A patent/MA40547A/fr unknown
- 2015-08-07 US US15/501,730 patent/US10597390B2/en not_active Expired - Fee Related
- 2015-08-07 UA UAA201702154A patent/UA124609C2/uk unknown
- 2015-08-07 JP JP2017506964A patent/JP6577570B2/ja not_active Expired - Fee Related
- 2015-08-07 KR KR1020177005979A patent/KR102488479B1/ko active Active
-
2017
- 2017-02-02 PH PH12017500207A patent/PH12017500207A1/en unknown
- 2017-02-02 IL IL250408A patent/IL250408B/en active IP Right Grant
- 2017-02-07 ZA ZA2017/00952A patent/ZA201700952B/en unknown
- 2017-02-07 CL CL2017000309A patent/CL2017000309A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10597390B2 (en) | 2020-03-24 |
| ZA201700952B (en) | 2018-12-19 |
| IL250408A0 (en) | 2017-03-30 |
| KR20170039275A (ko) | 2017-04-10 |
| JP2017523225A (ja) | 2017-08-17 |
| MX381488B (es) | 2025-03-12 |
| CA2954751C (en) | 2023-01-17 |
| SG11201700956VA (en) | 2017-03-30 |
| CA2954751A1 (en) | 2016-02-11 |
| AU2015298876B2 (en) | 2020-02-13 |
| EP3177609A1 (en) | 2017-06-14 |
| WO2016020526A1 (en) | 2016-02-11 |
| AU2015298876A1 (en) | 2017-02-02 |
| BR112017002370A2 (pt) | 2017-12-05 |
| MX2017001752A (es) | 2018-02-08 |
| US20170226102A1 (en) | 2017-08-10 |
| BR112017002370B1 (pt) | 2022-11-22 |
| KR102488479B1 (ko) | 2023-01-12 |
| EA201790266A1 (ru) | 2017-06-30 |
| CN106573920A (zh) | 2017-04-19 |
| PH12017500207B1 (en) | 2017-07-10 |
| JP6577570B2 (ja) | 2019-09-18 |
| CN106573920B (zh) | 2020-11-10 |
| CL2017000309A1 (es) | 2017-08-18 |
| PH12017500207A1 (en) | 2017-07-10 |
| MA40547A (fr) | 2017-06-14 |
| IL250408B (en) | 2020-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA124609C2 (uk) | Індоли для застосування при інфекції, спричиненій вірусом грипу | |
| US11306101B2 (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | |
| JP3167788B2 (ja) | 肝炎の処置に有用な１，３−オキサチオラン | |
| EA037529B1 (ru) | Способ получения соединения для ингибирования репликации вирусов гриппа | |
| CZ262494A3 (en) | The use of medicaments for action potentiation and a pharmaceutical preparation | |
| US11713295B2 (en) | Psychotropic agents and uses thereof | |
| WO2022169864A1 (en) | Methods for treating spinocerebellar ataxia type 3 | |
| UA122808C2 (uk) | Інгібітори реплікації вірусів грипу | |
| UA75325C2 (en) | Antiparasitic derivatives of artemisin (endoperoxides) | |
| CN109071529A (zh) | 作为jak激酶抑制剂的嘧啶化合物 | |
| EP3814380A1 (en) | Bispecific degraders | |
| US20210379020A1 (en) | Compounds for the treatment of malaria | |
| US20220348558A1 (en) | Inhibitors of encephalitic alphaviruses | |
| US20210338683A1 (en) | Treatment of viral infections with combination of pikfyve kinase inhibitors and tmprss-2 inhibitors | |
| US20230098667A1 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| WO2022126857A1 (zh) | 二维纳米材料在抑制冠状病毒的应用 | |
| UA76887C2 (uk) | Сполука піперидину | |
| WO2016176399A1 (en) | Compositions and methods for treatment of pulmonary hypertension | |
| HK1201181A1 (en) | Novel cyclosporin derivatives for the treatment and prevention of viral infections | |
| JP5756096B2 (ja) | グアニンリボスイッチ結合化合物及び抗生物質としてのその使用 | |
| CN116549642A (zh) | p23蛋白抑制剂用于抑制和/或杀灭病毒的产品 | |
| CN110448554A (zh) | D-青霉胺联合氟康唑在制备抗真菌产品中的应用 | |
| EP4573090A1 (en) | Isoxazolidines as ripk1 inhibitors and use thereof | |
| US11655225B2 (en) | Antimycobacterial heterocyclic amides | |
| US20220088002A1 (en) | Method against coronavirus infection with quinoline compound |